Terapevticheskii arkhivTerapevticheskii arkhivТерапевтический архив0040-36602309-5342LLC Obyedinennaya Redaktsiya8297810.26442/00403660.2021.09.201036ReviewsОбзорыResearch ArticleCOVID-19 and features of cardiovascular involvementCOVID-19 и особенности вовлечения сердечно-сосудистой системыhttps://orcid.org/0000-0002-3410-2510TsyganovaElena V.ЦыгановаЕлена Валерьевна
Russian Federation

канд. мед. наук, врач-инфекционист, зав. научно-клиническим отд. МГЦ СПИД

ndlena@mail.ruhttps://orcid.org/0000-0003-2414-6103GlukhoedovaNataliia V.ГлухоедоваНаталия Владимировна
Russian Federation

канд. мед. наук, врач-инфекционист научно-клинического отд. МГЦ СПИД

ndlena@mail.ruhttps://orcid.org/0000-0001-8139-4061ZhilenkovaAleksandra S.ЖиленковаАлександра Сергеевна
Russian Federation

врач-инфекционист научно-клинического отд. МГЦ СПИД

ndlena@mail.ruhttps://orcid.org/0000-0003-2888-3995FedoseevaTatiana I.ФедосееваТатьяна Ивановна
Russian Federation

врач ультразвуковой диагностики ООО СП №1

ndlena@mail.ruhttps://orcid.org/0000-0003-0065-5624IushchukElena N.ЮщукЕлена Николаевна
Russian Federation

д-р мед. наук, проф., зав. каф. клинической функциональной диагностики лечебного фак-та ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»

ndlena@mail.ruhttps://orcid.org/0000-0002-2131-387XSmetnevaNatalia S.СметневаНаталья Сергеевна
Russian Federation

канд. мед. наук, ассистент каф. факультетской терапии и профболезней ФГБОУ ВО «МГМСУ им. А.И. Евдокимова»; доц. каф. клинической медицины ЧУОО ВО «Медицинский университет “Реавиз”»

ndlena@mail.ruMoscow City Center for the Prevention and Control of AIDS«Московский городской центр профилактики и борьбы со СПИД» Департамента здравоохранения г. МосквыFamily Polyclinic №1ООО «Семейная поликлиника №1»Yevdokimov Moscow State University of Medicine and DentistryФГБОУ ВО «Московский государственный медико-стоматологический университет им. А.И. Евдокимова» Минздрава РоссииMedical University “Reaviz“ЧУОО ВО «Медицинский университет “Реавиз”»15092021939109110991010202110102021Copyright ©; 2021, Consilium MedicumCopyright ©; 2021, ООО "Консилиум Медикум"2021Consilium MedicumООО "Консилиум Медикум"https://creativecommons.org/licenses/by-nc-sa/4.0https://ter-arkhiv.ru/0040-3660/article/view/82978

The article provides an overview of current information on the pathogenesis of COVID-19 and organ-specific lesions developing in this disease. The data on inflammation and its biochemical markers, on the features of coagulopathy, endothelial damage and microthrombosis are presented in detail. Particular attention is paid to the role of receptors for angiotensin converting enzyme type 2 and transmembrane serine protease type 2 in the development of organ-specific lesions in COVID-19. The pathogenesis of damage to the cardiovascular system is considered in detail with the presentation of data from foreign literature on changes in the myocardium and the author's results of transthoracic echocardiographic examination in patients who have undergone COVID-19.

Представлен обзор современных сведений о патогенезе COVID-19 и органоспецифических поражениях, развивающихся при этом заболевании. Подробно отражены данные о воспалении и его биохимических маркерах, об особенностях коагулопатии, поражении эндотелия и микротромбозах. Особое внимание уделяется роли рецепторов ангиотензинпревращающего фермента 2-го типа и трансмембранной сериновой протеазы 2-го типа в развитии органоспецифических поражений при COVID-19. Детально рассмотрен патогенез поражения сердечно-сосудистой системы с представлением данных зарубежной литературы об изменениях миокарда и авторских результатов трансторакального эхокардиографического исследования у больных, перенесших COVID-19.

COVID-19myocardial changestransthoracic echocardiographyinflammationcoagulationthrombosisCOVID-19изменения миокардатрансторакальная эхокардиографиявоспалениекоагуляциятромбозGuan W, Ni ZY, Yu Hu, et al. Clinical Characteristics of Coronavirus Disease 2019 in China. N Engl J Med. 2020;382(18):1708-20. DOI:10.1056/NEJMoa2002032Fang L, Karakiulakis G, Roth M. Are patients with hypertension and diabetes mellitus at increased risk for COVID-19 infection? Lancet Respir Med. 2020;8(4):e21. DOI:10.1016/s2213-2600(20)30116-8Misra D, Agarwal V, Gasparyan AOZ. Rheumatologists’ perspective on coronavirus disease 19 (COVID-19) and potential therapeutic targets. Clin Rheumatol. 2020;39(7):2055-62. DOI:10.1007/s10067-020-05073-9Huang C, Wang Y, Li X, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. DOI:10.1016/S0140-6736(20)30183-5Mehta P, McAuley DF, Brown M, et al. COVID-19: consider cytokine storm syndromes and immunosuppression. Lancet. 2020;395(10229):1033-4. DOI:10.1016/S0140-6736(20)30628-0Xu X, Han M, Li T, et al. Effective treatment of severe COVID-19 patients with tocilizumab. Proc Natl Acad Sci. 2020;117(20):10970-5. DOI:10.1073/pnas.2005615117McGonagle D, O`Donnell JS, Sharif K, et al. Immune mechanisms of pulmonary intravascular coagulopathy in COVID-19 pneumonia. Lancet Rheumatol. 2020;2(7):e437-45. DOI:10.1016/S2665-9913(20)30121-1Tang N, Li D, Wang X, et al. Abnormal coagulation parameters are associated with poor prognosis in patients with novel coronavirus pneumonia. J Thromb Haemost. 2020;18(4):844-7. DOI:10.1111/jth.14768McGonagle D, Sharif K, O'Regan A, et al. The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease. Autoimmun Rev. 2020;19):1-7. DOI:10.1016/j.autrev.2020.102537Behzad S, Aghaghazvini L, Radmard AR, Gholamrezanezhad A. Extrapulmonary manifestations of COVID-19: Radiologic and clinical overview. Clin Imaging. 2020;66:35-41. DOI:10.1016/j.clinimag.2020.05.013Dong M, Zhang J, Ma X, et al. ACE2, TMPRSS2 distribution and extrapulmonary organ injury in patients with COVID-19. Biomed Pharmacother. 2020;131. DOI:10.1016/j.biopha.2020.110678Zou X, Chen K, Zou J, et al. Single-cell RNA-seq data analysis on the receptor ACE2 expression reveals the potential risk of different human organs vulnerable to 2019-nCoV infection. Front Med. 2020;14(2):185-92. DOI:10.1007/s11684-020-0754-0Pan XW, Xu D, Zhang H, et al. Identification of a potential mechanism of acute kidney injury during the COVID-19 outbreak: a study based on single-cell transcriptome analysis. Int Care Med. 2020;46(6):1114-6. DOI:10.1007/s00134-020-06026-1Zhang H, Kang Z, Gong H, et al. The digestive system is a potential route of 2019-nCov infection: A bioinformatics analysis based on single-cell transcriptomes. BioRxiv. 2020:2020.01.30.927806. DOI:10.1101/2020.01.30.927806Guo AX, Cui JJ, OuYang QY, et al. The clinical characteristics and mortal causes analysis of COVID-19 death patients. MedRxiv. 2020. DOI:10.1101/2020.04.12.20062380Chen L, Li X, Chen M, et al. The ACE2 expression in human heart indicates new potential mechanism of heart injury among patients infected with SARS-CoV-2. Cardiovasc Res. 2020;116(6):1097-100. DOI:10.1093/cvr/cvaa078Seow J, Pai R, Mishra A. ScRNA-seq reveals ACE2 and TMPRSS2 expression in TROP2+ Liver Progenitor Cells: Implications in COVID-19 associated Liver Dysfunction. BioRxiv. 2020. DOI:10.1101/2020.03.23.002832Ackermann M, Verleden SE, Kuehnel M, et al. Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19. N Engl J Med. 2020;383:120-8. DOI:10.1056/NEJMoa2015432Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: A marker of atherosclerotic risk. Arteriosclerosis, Thrombosis, and Vascular Biology. Arterioscler Thromb Vasc Biol. 2003;23(2):168-75. DOI:10.1161/01.ATV.0000051384.43104.FCCampbell CM, Kahwash R. Will Complement Inhibition Be the New Target in Treating COVID-19-Related Systemic Thrombosis? Circulation. 2020;141(22):1739-41. DOI:10.1161/CIRCULATIONAHA.120.047419Wang X, Sahu KK, Cerny J. Coagulopathy, endothelial dysfunction, thrombotic microangiopathy and complement activation: potential role of complement system inhibition in COVID-19. J Thromb. 2020:1-6. DOI:10.1007/s11239-020-02297-zIba T, Levy JH, Connors JM, et al. The unique characteristics of COVID-19 coagulopathy. Crit Care. 2020;24(1). DOI:10.1186/s13054-020-03077-0Driggin E, Madhavan MV, Bikdeli B, et al. Cardiovascular Considerations for Patients, Health Care Workers, and Health Systems During the COVID-19 Pandemic. J Am Col Cardiol. 2020;75(18):2352-71. DOI:10.1016/j.jacc.2020.03.031Clerkin KJ, Fried JA, Raikhelkar J, et al. COVID-19 and Cardiovascular Disease. Circulation. 2020;141:1648-55. DOI:10.1161/CIRCULATIONAHA.120.046941Hu H, Ma F, Wei X, Fang Y. Coronavirus fulminant myocarditis saved with glucocorticoid and human immunoglobulin. Eur Heart J. 2021;42(2):206. DOI:10.1093/eurheartj/ehaa190Inciardi RM, Lupi L, Zaccone G, et al. Cardiac Involvement in a Patient with Coronavirus Disease 2019 (COVID-19). JAMA Cardiol. 2020;5(7):819-24. DOI:10.1001/jamacardio.2020.1096Wei X, Fang Y, Hu H. Glucocorticoid and immunoglobulin to treat viral fulminant myocarditis. Eur Heart J. 2020;41(22):2122. DOI:10.1093/eurheartj/ehaa357Agricola E, Beneduce A, Esposito A, et al. Heart and Lung Multimodality Imaging in COVID-19. JACC Cardiovasc Imaging. 2020;13(8):1792-808. DOI:10.1016/j.jcmg.2020.05.017Oudit GY, Kassiri Z, Jiang C, et al. SARS-coronavirus modulation of myocardial ACE2 expression and inflammation in patients with SARS. Eur J Clin Invest. 2009;39(7):618-25. DOI:10.1111/j.1365-2362.2009.02153.xSala S, Peretto G, Gramegna M, et al. Acute myocarditis presenting as a reverse Tako-Tsubo syndrome in a patient with SARS-CoV-2 respiratory infection. Eur Heart J. 2020;41(19):1861-2. DOI:10.1093/eurheartj/ehaa286Doyen D, Moceri P, Ducreux D, Dellamonica J. Myocarditis in a patient with COVID-19: a cause of raised troponin and ECG changes. Lancet. 2020;395(10235):1516. DOI:10.1016/S0140-6736(20)30912-0Hua A, O'Gallagher K, Sado D, Byrne J. Life-threatening cardiac tamponade complicating myo-pericarditis in COVID-19. Eur Heart J. 2020;41(22):2130. DOI:10.1093/eurheartj/ehaa253Xu Z, Shi L, Wang Y, et al. Case Report Pathological findings of COVID-19 associated with acute respiratory distress syndrome. Lancet Respir Med. 2020;8(4):420-2. DOI:10.1016/S2213-2600(20)30076-XFrangogiannis NG. The inflammatory response in myocardial injury, repair and remodeling. Nat Rev Cardiol. 2014;11(5):255-65. DOI:10.1038/nrcardio.2014.28Agewall S, Beltrame JF, Reynolds HR, et al. ESC working group position paper on myocardial infarction with non-obstructive coronary arteries. Eur Heart J. 2017;38(3):143-53. DOI:10.1093/eurheartj/ehw149Aghagoli G, Gallo Marin B, Soliman LB, Sellke FW. Cardiac involvement in COVID-19 patients: Risk factors, predictors, and complications: A review. J Card Surg. 2020;35(6):1302-5. DOI:10.1111/jocs.14538Puntmann VO, Carerj ML, Wieters I, et al. Outcomes of Cardiovascular Magnetic Resonance Imaging in Patients Recently Recovered From Coronavirus Disease 2019 (COVID-19) Editorial Supplemental content. JAMA Cardiol. 2020;5(11):1265-73. DOI:10.1001/jamacardio.2020.3557Puntmann VO, Valbuena S, Hinojar R, et al. Society for Cardiovascular Magnetic Resonance (SCMR) expert consensus for CMR imaging endpoints in clinical research: Part I – Analytical validation and clinical qualification. J Cardiovas Magn Reson. 2018;20(1). DOI:10.1186/s12968-018-0484-5